Handok Inc.

Quick facts

Marketed products

• Ciclesonide & Levocetirizine · Respiratory / Allergy / Immunology
  Ciclesonide is an inhaled corticosteroid that reduces airway inflammation, while levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.
• Glimepiride/metformin fixed combination · Diabetes
  This combination reduces blood glucose by stimulating insulin secretion from pancreatic beta cells (glimepiride) and decreasing hepatic glucose production while improving insulin sensitivity (metformin).

Phase 3 pipeline

• Irbesartan/Amlodipine · Cardiovascular
  This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.
• Irbesartan/Amlodipine high · Cardiovascular
  This combination drug blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance.
• Irbesartan/Amlodipine low · Cardiovascular
  This combination drug lowers blood pressure by blocking angiotensin II receptors (irbesartan) and calcium channels (amlodipine) to reduce vascular resistance and improve blood flow.
• Ketoprofen topical · Pain Management, Rheumatology
  Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.
• MP513 · Respiratory/Pulmonology
  MP513 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• Teneligliptin Placebo Oral Tablet · Diabetes
  Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion.

Phase 2 pipeline

• Amlodipine High · Cardiovascular
  Calcium channel blocker

Phase 1 pipeline

• HD-P023
• Irbesartan High
• Teneligliptin and Empagliflozin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Handok Inc. portfolio CI brief
• Handok Inc. pipeline updates RSS